Add-on Acquisition • Life Science

Xcovery Acquires Meryx

On December 7, 2021, Xcovery acquired life science company Meryx

Acquisition Context

This is Xcovery’s 1st transaction in the Life Science sector.
This is Xcovery’s 1st transaction in the United States.
This is Xcovery’s 1st transaction in North Carolina.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	December 7, 2021
Target	Meryx
Sector	Life Science
Buyer(s)	Xcovery
Deal Type	Add-on Acquisition

Target Company

Meryx

Chapel Hill, North Carolina, United States

Meryx is a clinical stage immuno-oncology company focused on advancing small molecule, orally bioavailable inhibitors of Mer Receptor Tyrosine Kinase (RTK) that inhibit growth and initiate anti-tumor immunity in a range of hematologic and solid malignancies. Meryx is based in Chapel Hill, North Carolina.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Xcovery

Palm Beach Gardens, Florida, United States

Category	Company
Founded	2006
Sector	Life Science

DESCRIPTION

Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering and developing small molecules that precisely target cancer growth mechanisms. Xcovery was founded in 2006 and is based in Palm Beach Gardens, Florida.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: North Carolina	1 of 1
Country: United States	1 of 1
Year: 2021	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - North Carolina M&A - United States M&A - 2021 M&A